tumor protein p53

Overview

Tumor protein p53 (TP53) is one of the most extensively studied tumor suppressor genes in biomedical research, encoding the p53 protein—a transcription factor critical to maintaining genomic integrity. The p53 protein functions as a master regulator of the cellular stress response, binding to target gene promoters to orchestrate a broad network of downstream effects including apoptosis, cell cycle arrest, autophagy, metabolic reprogramming, cellular senescence, and modulation of the tumor immune microenvironment. Through these mechanisms, p53 acts as a central guardian against malignant transformation. Under conditions of genotoxic stress, oncogene activation, or hypoxia, p53 becomes stabilized and transcriptionally active, driving expression of genes that suppress tumor development and progression. Its regulation intersects with multiple co-factors and pathway members including PTEN, BRCA1, PARP1, and sirtuin 1 (SIRT1), reflecting its integration into a wide network of DNA damage response and chromatin-modifying machinery.

Mutation or functional loss of TP53 is among the most frequent molecular events observed across human cancers. Missense mutations—most commonly affecting the DNA-binding domain—impair p53's ability to recognize and transactivate target sequences, conferring both loss-of-function and, in many cases, gain-of-function oncogenic properties. The Y220C substitution is a well-characterized destabilizing mutation that causes structural unfolding of the p53 DNA-binding domain. Disruption of p53 signaling permits malignant cells to evade apoptosis, accumulate further genomic instability, and resist therapeutic pressure, making TP53 status a key determinant of cancer prognosis and a high-priority target for therapeutic intervention.

Focus of Latest Publications

Recent publications highlight p53 as a central target in cancer therapeutics and beyond, with research focusing on three major strategies: restoration of mutant p53 function, enhancement of wild-type p53-mediated apoptosis, and correction of TP53 mutations through gene therapy.

For the frequent p53 Y220C mutation, investigators developed multiple approaches to reactivate the compromised tumor suppressor. Small-molecule covalent agonists targeting the neomorphic pocket created by this mutation restored DNA-binding capacity and suppressed tumor cell growth, while the oral selective p53 reactivator rezatapopt stabilizes Y220C-mutated p53 in its wild-type conformation. Notably, MDM2-targeted degraders proved superior to MDM2 inhibitors by collapsing the p53/MDM2 negative feedback loop that normally blunts inhibitor efficacy, producing deep and durable tumor regressions including complete responses in patient-derived xenograft models.

Wild-type p53 activation emerged as the mechanism underlying several innovative therapeutic modalities. Nanoemulsion-based delivery of plant-derived compounds, glucose transporter inhibitors, and gold-ceria nanohybrids all converged on p53-mediated apoptosis through activation of p53/p21/caspase-3 signaling pathways and mitochondrial dysfunction. In hepatocellular carcinoma, modulation of the PTEN/AKT/p53 axis controlled cell cycle progression and apoptosis. Gene-editing approaches, including CRISPR-supported nanoparticles designed to enhance TP53 expression while silencing oncogenes, and homologous recombination-based TP53 correction strategies, offered precision methods to restore p53 function in tumors harboring TP53 mutations.

Beyond oncology, emerging evidence suggests p53 regulation extends to other disease contexts, with mechanistic studies identifying p53 as part of regulatory axes affecting cellular senescence and tissue pathology, indicating potential therapeutic applications beyond cancer treatment.

Key Publications

• NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42406222)
• NEWJul Multi-omics integration identifies macrophage senescence driven by the RUNX1-P53 axis as a key mechanism in diabetic foot ulcer. (Functional & integrative genomics, 2026, PMID 42399485): "RUNX1, upregulated under diabetic conditions, and is associated with promoted P53 acetylation."
• NEWJul Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models. (The Journal of clinical investigation, 2026, PMID 42383359): "MDM2 suppresses p53 and is a rational therapeutic target."
• NEWJul CNOT9 affects hepatocellular carcinoma proliferation and cell cycle through the PTEN/AKT/p53 signaling pathway. (Human cell, 2026, PMID 42384246): "CNOT9 knockdown activates PTEN to inhibit the AKT pathway and suppresses the expression of cell cycle-related proteins p53, p21, CCNE1 and CDK2."
• NEWJun Biomedical publication details. (PubMed Database, 2026, PMID 42315971)
• Jun Biomedical publication details. (PubMed Database, 2026, PMID 42240071)
• Apr [Novel clinical insights and frontier issues in alpha- fetoprotein-producing gastric cancer]. (Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2026, PMID 41978393): "Most cases are classified under the chromosomal instability (CIN) subtype, featuring a molecular signature often marked by TP53 and MUC16 mutations, as well as significant amplifications of genes like ERBB2 and the cell cycle regulator CCNE1."
• Mar Discovery of novel covalent agonists for p53 Y220C through synergistic strategy combining covalent binding and scaffold hopping. (European journal of medicinal chemistry, 2026, PMID 41934688): "Consequently, activating the antitumor function of p53 mutants emerges as a promising therapeutic strategy for diverse malignancies."
• Apr Ultrasound-Enhanced CRISPR-Curcumin Nanoparticles for Gene-Modulating Therapy in Metastatic Pulmonary Lesions. (Cancer biotherapy & radiopharmaceuticals, 2026, PMID 41882965): "This study evaluates CRISPR-supported, curcumin-loaded polymeric nanoparticles (CRISPR-CuNPs) designed to silence the KRAS-G12D oncogene while enhancing tumor-suppressor gene expression (TP53, PTEN) in metastatic pulmonary cancer cells."
• Apr CRISPR-mediated cancer therapies: Approaches to direct tumor targeting. (Critical reviews in oncology/hematology, 2026, PMID 41833894): "TP53 correction through homologous recombination, which uses a donor DNA template to repair mutant sequences at the targeted locus;"